Search

everythinglearnresearchcommunity

for

Search:↓

The combination treatment showed a higher response rate but no significant survival benefits.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

An imbalanced scalp microbiome may worsen alopecia areata severity and inflammation, but treatment can partially restore balance.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Baricitinib works better than methotrexate for severe alopecia areata.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Longer immunotherapy treatment may improve outcomes for Merkel cell carcinoma patients.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Rituximab can cause skin issues, but baricitinib may help improve them.

Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.

Clofazimine effectively treated ashy dermatosis in a patient.

Baricitinib is effective as a treatment for severe hair loss.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.